Canaccord raised the firm’s price target on DexCom (DXCM) to $100 from $95 and keeps a Buy rating on the shares. The firm said they reported alighlty better than expected revenue but the more important metric was significantly better-than-expected adjusted GM, which drove significantly higher adjusted OMs and adjusted EBITDA. Guidance was raised, but to reflect only the Q1 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target lowered to $67 from $72 at Barclays
- Buy Rating Reaffirmed on Dexcom as Margin Strength and Global Patient Growth Offset U.S. CGM Concerns; Price Target Reset to $75
- Closing Bell Movers: Apple higher after stronger than expected guidance
- DexCom affirms FY26 revenue $5.16B-$5.25B, consensus $5.23B
- DexCom reports Q1 EPS 56c, consensus 47c